Am J Gastroenterol . Caution With the Use of Lopinavir/Ritonavir in Severely Ill Patients for the Treatment of SARS-CoV-2: A Report of Severe Jaundice

[tetano]

Am J Gastroenterol


. 2020 Aug 27.
doi: 10.14309/ajg.0000000000000828. Online ahead of print.
Caution With the Use of Lopinavir/Ritonavir in Severely Ill Patients for the Treatment of SARS-CoV-2: A Report of Severe Jaundice


Clementine Levy ¹ , Guillaume Lassailly ² , Erika Parmentier ¹ , Thibault Duburcq ¹ , Philippe Mathurin ² , Julien Poissy ¹



Affiliations

• PMID: 32858566
• DOI: 10.14309/ajg.0000000000000828

Abstract

Introduction: We investigated the potential hepatotoxicity of lopinavir/ritonavir recently used in the treatment of Severe Acute Respiratory Syndrome Coronavirus.
Methods: This is a retrospective cohort of critical patients in a teaching hospital: 12 treated with lopinavir/ritonavir and 30 in the standard-of-care group.
Results: Elevation occurred more frequently in patients treated with lopinavir/ritonavir (33% vs 6.7%).
Discussion: Caution is advised regarding the use of lopinavir/ritonavir in the most severe cases of Severe Acute Respiratory Syndrome Coronavirus.